Research ArticleNeuropharmacology
The Unique α4(+)/(−)α4 Agonist Binding Site in (α4)3(β2)2 Subtype Nicotinic Acetylcholine Receptors Permits Differential Agonist Desensitization Pharmacology versus the (α4)2(β2)3 Subtype
J. Brek Eaton, Linda M. Lucero, Harrison Stratton, Yongchang Chang, John F. Cooper, Jon M. Lindstrom, Ronald J. Lukas and Paul Whiteaker
Journal of Pharmacology and Experimental Therapeutics January 2014, 348 (1) 46-58; DOI: https://doi.org/10.1124/jpet.113.208389
J. Brek Eaton
Division of Neurobiology, Barrow Neurologic Institute, Phoenix, Arizona (J.B.E., L.M.L., H.S., Y.C., R.J.L., P.W.); and Department of Neuroscience, Medical School of the University of Pennsylvania, Philadelphia, Pennsylvania (J.F.C., J.M.L.)
Linda M. Lucero
Division of Neurobiology, Barrow Neurologic Institute, Phoenix, Arizona (J.B.E., L.M.L., H.S., Y.C., R.J.L., P.W.); and Department of Neuroscience, Medical School of the University of Pennsylvania, Philadelphia, Pennsylvania (J.F.C., J.M.L.)
Harrison Stratton
Division of Neurobiology, Barrow Neurologic Institute, Phoenix, Arizona (J.B.E., L.M.L., H.S., Y.C., R.J.L., P.W.); and Department of Neuroscience, Medical School of the University of Pennsylvania, Philadelphia, Pennsylvania (J.F.C., J.M.L.)
Yongchang Chang
Division of Neurobiology, Barrow Neurologic Institute, Phoenix, Arizona (J.B.E., L.M.L., H.S., Y.C., R.J.L., P.W.); and Department of Neuroscience, Medical School of the University of Pennsylvania, Philadelphia, Pennsylvania (J.F.C., J.M.L.)
John F. Cooper
Division of Neurobiology, Barrow Neurologic Institute, Phoenix, Arizona (J.B.E., L.M.L., H.S., Y.C., R.J.L., P.W.); and Department of Neuroscience, Medical School of the University of Pennsylvania, Philadelphia, Pennsylvania (J.F.C., J.M.L.)
Jon M. Lindstrom
Division of Neurobiology, Barrow Neurologic Institute, Phoenix, Arizona (J.B.E., L.M.L., H.S., Y.C., R.J.L., P.W.); and Department of Neuroscience, Medical School of the University of Pennsylvania, Philadelphia, Pennsylvania (J.F.C., J.M.L.)
Ronald J. Lukas
Division of Neurobiology, Barrow Neurologic Institute, Phoenix, Arizona (J.B.E., L.M.L., H.S., Y.C., R.J.L., P.W.); and Department of Neuroscience, Medical School of the University of Pennsylvania, Philadelphia, Pennsylvania (J.F.C., J.M.L.)
Paul Whiteaker
Division of Neurobiology, Barrow Neurologic Institute, Phoenix, Arizona (J.B.E., L.M.L., H.S., Y.C., R.J.L., P.W.); and Department of Neuroscience, Medical School of the University of Pennsylvania, Philadelphia, Pennsylvania (J.F.C., J.M.L.)

Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleNeuropharmacology
HS vs. LS α4β2 Nicotinic Receptor Agonist Desensitization
J. Brek Eaton, Linda M. Lucero, Harrison Stratton, Yongchang Chang, John F. Cooper, Jon M. Lindstrom, Ronald J. Lukas and Paul Whiteaker
Journal of Pharmacology and Experimental Therapeutics January 1, 2014, 348 (1) 46-58; DOI: https://doi.org/10.1124/jpet.113.208389
Research ArticleNeuropharmacology
HS vs. LS α4β2 Nicotinic Receptor Agonist Desensitization
J. Brek Eaton, Linda M. Lucero, Harrison Stratton, Yongchang Chang, John F. Cooper, Jon M. Lindstrom, Ronald J. Lukas and Paul Whiteaker
Journal of Pharmacology and Experimental Therapeutics January 1, 2014, 348 (1) 46-58; DOI: https://doi.org/10.1124/jpet.113.208389
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement